TABLE 1.

Susceptibilities of C. dubliniensis isolates from AIDS patients to a panel of antifungal agents

Patient no.IsolateSourceaDate (mo/day/yr)MICs (μg/ml) at 24 h/48 hb
FLCITCVRCPSZRAVAMBMKc
13300C-07/15/960.5/1<0.015/<0.015<0.015/<0.015<0.015/<0.015<0.008/0.016<0.03/0.060.5/0.5
3323C-07/22/968/160.03/0.250.06/0.25<0.015/0.060.03/0.250.06/0.060.5/0.5
3592C-010/22/9616/32<0.015/0.1250.125/0.25<0.015/0.030.016/0.06<0.03/0.060.5/0.5
3946C-02/14/972/64<0.015/0.1250.06/0.25<0.015/0.030.008/0.03<0.03/0.060.5/0.5
4379C-87/10/974/4<0.015/0.030.03/0.06<0.015/<0.015<0.008/0.0160.03/0.060.5/0.5
4380C-167/10/9732/640.03/0.250.25/0.25<0.015/0.06<0.008/0.250.03/0.060.5/0.5
4713C-89/9/9732/64<0.015/0.250.06/0.25<0.015/0.060.06/0.25<0.03/0.060.5/0.5
4806C-010/8/9732/64<0.015/0.1250.125/0.125<0.015/0.030.016/0.006<0.03/0.060.5/0.5
4807C-010/8/9716/32<0.015/0.1250.125/0.125<0.015/0.03<0.008/0.016<0.03/0.060.5/0.5
5143C-01/8/9816/32<0.015/0.1250.125/0.25<0.015/0.030.016/0.06<0.03/0.060.5/0.5
5258C-01/8/981/1<0.015/0.03<0.015/0.06<0.015/<0.015<0.008/0.016<0.03/0.060.5/0.5
5259C-01/8/988/16<0.015/0.030.03/0.25<0.015/<0.015<0.008/0.016<0.03/0.060.5/0.5
23466C-09/4/960.25/0.25<0.015/0.03<0.015/0.03<0.015/0.06<0.008/0.016<0.03/0.060.5/0.5
3538C-010/14/96<0.125/0.25<0.015/0.125<0.015/0.125<0.015/0.125<0.008/0.016<0.03/0.060.5/0.5
3853C-81/29/9716/32<0.015/0.125<0.015/0.250.03/0.1250.125/0.25<0.03/0.060.5/0.5
3870C-82/6/9716/32<0.015/0.1250.25/0.250.06/0.1250.125/0.25<0.03/0.060.5/0.5
4572C-08/19/9732/64<0.015/0.250.06/0.25<0.015/0.1250.25/0.5<0.03/0.060.5/0.5
4573C-88/19/9716/32<0.015/0.06<0.015/0.06<0.015/0.060.06/0.25<0.03/0.060.5/0.5
  • a C-0, CHROMagar without FLU; C-8, CHROMagar with 8 μg of FLC/ml; C-16, CHROMagar with 16 μg of FLC/ml.

  • b ITC, itraconazole; VRC, voriconazole; PSZ, posaconazole; RAV, ravuconazole; AMB, amphotericin B; MK, caspofungin.

  • c RPMI medium was used.